Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model

Aart C. Strang1☯, Menno L. W. Knetsch2☯, Leo H. Koole2, Robbert J. de Winter3, Allard C. van der Wal4, Carlie J. M. de Vries5, Paul P. Tak6, Radjesh J. Biscoendial7, Erik S. G. Stroes1*, Joris I. Rotmans8

1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands, 2 Department of Biomedical Engineering/Biomaterials Science, Maastricht University, Maastricht, The Netherlands, 3 Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands, 4 Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands, 5 Department of Biochemistry, Academic Medical Center, Amsterdam, The Netherlands, 6 Department of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands, 7 Heart Research Institute, Newtown, NSW 2042, Australia; and Centenary Institute, Newtown, NSW, 2042, Australia, 8 Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands

☯ These authors contributed equally to this work.
* e.s.stroes@amc.uva.nl

Abstract

Background and Aims

Since high-density lipoprotein (HDL) has pro-endothelial and anti-thrombotic effects, a HDL recruiting stent may prevent restenosis. In the present study we address the functional characteristics of an apolipoprotein A-I (ApoA-I) antibody coating in vitro. Subsequently, we tested its biological performance applied on stents in vivo in rabbits.

Materials and Methods

The impact of anti-ApoA-I- versus apoB-antibody coated stainless steel discs were evaluated in vitro for endothelial cell adhesion, thrombin generation and platelet adhesion. In vivo, response to injury in the iliac artery of New Zealand white rabbits was used as read out comparing apoA-I-coated versus bare metal stents.

Results

ApoA-I antibody coated metal discs showed increased endothelial cell adhesion and proliferation and decreased thrombin generation and platelet adhesion, compared to control discs. In vivo, no difference was observed between ApoA-I and BMS stents in lumen stenosis (23.3±13.8% versus 23.3±11.3%, p=0.77) or intima surface area (0.81±0.62 mm² vs 0.84±0.55 mm², p=0.85). Immunohistochemistry also revealed no differences in cell proliferation, fibrin deposition, inflammation and endothelialization.
Conclusion

ApoA-I antibody coating has potent pro-endothelial and anti-thrombotic effects in vitro, but failed to enhance stent performance in a balloon injury rabbit model in vivo.

Introduction

The introduction of stents has increased the success of percutaneous coronary interventions (PCI) by reducing coronary artery restenosis rates. This advantage, however, comes at a price. Bare metal stents (BMS) are more prone to in-stent restenosis (ISR) and their pro-thrombotic capacity may yield occlusion rates of up to 24% in the absence of pharmacological treatment. Drug-eluting stents (DES) have proven highly effective through local delivery of antiproliferative drugs, albeit the imminent threat of late stent thrombosis (LST) has hampered their success. Thus, a comparative meta-analysis revealed that long-term cardiac death rates for BMS and DES were not significantly different. These results highlight the need for novel stents with better long-term performance compared to both BMS and DES.

We hypothesized that stent performance could be enhanced by coating the stent struts with anti-apolipoprotein A-I (ApoA-I) antibodies, aimed to attract high-density lipoprotein (HDL) to the stent. Indeed, HDL has been shown to carry a wide array of anti-inflammatory and antiproliferative proteins, which collectively have the capacity to prevent intimal hyperplasia. In addition, HDL has also been shown to promote recruitment of endothelial progenitor cells, thereby promoting restoration of an intact endothelial monolayer covering the stent struts as well as the injured artery wall. The physiological role of the endothelium is expected to reduce the inflammatory response and decrease coagulation activation with subsequent thrombus formation.

In the present study, we evaluated the efficacy and therapeutic potential of anti-ApoA-I antibody coating on metal discs in vitro and bare metal stents in vivo. First, we addressed whether anti-ApoA-I coating improved the vascular homeostasis by improving endothelial cell adhesion, proliferation and decreasing thrombogenicity in vitro, compared to a bare-metal surface. Subsequently, we compared neointimal hyperplasia in a balloon-injury model in rabbits using an anti-ApoA-I coated versus bare-metal stent.

Methods

In vitro studies

The anti–human monoclonal ApoA-I antibody, ApoB100 antibody and isotype control IgG antibody were covalently coupled to stainless steel discs (5 mm diameter; double-sided). The surfaces with immobilized ApoA-I antibody (Clone 2F1, Ottawa Heart Institute Research Corporation, Ottawa, Canada) were treated with human HDL (Sigma-Aldrich, Zwijndrecht, The Netherlands) or oxidized (ox)-HDL (0.2 mg/ml). Oxidized lipoproteins were obtained by dialysis of 0.8 mg/ml solutions of HDL or LDL against 5 μM Cu SO4 for 20 hours and using Slide-A-Lyzer with MWCO of 3,500 (Thermo Fisher, Etten-Leur, The Netherlands). The surfaces with ApoB antibody (Clone 1D1, Ottawa Heart Institute Research Corporation) were incubated with human LDL (Sigma-Aldrich, Zwijndrecht, The Netherlands) or ox-LDL (0.2 mg/ml), while the surfaces with the isotype control IgG antibody were treated with a mixture of HDL and LDL or ox-HDL and ox-LDL (0.2 mg/ml). Ox-HDL, LDL and ox-LDL were used as negative control.
Human microvascular endothelial cells (HMEC-1; obtained from The Breakthrough Breast Cancer Research Center, London, England) were grown in MDCB-131 medium supplemented with 10% FBS, 2 mM L-glutamine, 1 μg/ml hydrocortisone, 10ng/ml recombinant h-EGF, and antibiotics (100U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B).[14] In order to determine proliferation of HMEC-1 on the different surfaces, metal discs were incubated for 1 hour with HDL, LDL, or a 1:1 mixture of both. After washing, HMEC-1 cells were deposited on the discs and allowed to adhere for 1 hour at 37 °C. After addition of medium, the discs were incubated for 1, 2 or 4 days. Subsequently, the discs were rinsed and frozen at -80°C. The number of adhered cells to the metal surfaces was determined using the CyQuant kit (Life Technologies, Breda, The Netherlands).[15]

In order to quantify HMEC-1 adhesion, pre-incubated metal discs were put in a sterile 2.0 ml tube and incubated with 1.5x10^5 cells in 0.8 ml MDCB-131 medium for 20 hours at 37 °C under rotation. After rinsing, discs were stored at -80°C. The number of adhered cells was determined using the CyQuant kit. Thrombin generation was determined in a static set-up, [16] (described in detail in S1 Text.

Platelet adhesion was determined using PRP that was prepared as described above. Metal discs were pre-incubated with HDL, LDL, or a HDL/LDL mixture and incubated with PRP for 1 hour at 37 °C under continuous stirring at 150 rpm. Subsequently, the discs were washed with phosphate buffered saline (PBS), and the number of adhered platelets was determined using the CytoTox kit (Promega, Leiden, The Netherlands).[17] The modified surfaces were incubated with native or oxidized versions of HDL or LDL and treated with PRP under identical conditions as described above. Oxidized HDL and LDL were used to rule out the effect of oxidative modification on platelet activation.[18] Platelet activation was studied by fixing platelets adhered to modified surfaces with cold 2.5% glutaraldehyde in PBS. After careful washing with PBS, the samples were dehydrated with an ethanol series followed by incubation in hexamethyldisilazane (Aldrich, Zwijndrecht, The Netherlands) in order to achieve rapid drying.[19] Subsequently the samples were sputter coated with gold and observed using a SEM (Philips XL30 Scanning Electron Microscope, Philips, Eindhoven, The Netherlands). Photographs of randomly chosen areas were taken, and the morphology of the platelets was recorded according to the method described by Cooper et al.[20]

**Stent coating.**  The anti–human monoclonal ApoA-I antibody was covalently coupled to struts of a 9mm x 3mm R-stent evolution 2 (OrbusNeich, US) at highest surface density (100%) using a proprietary multistep process (Ssens, The Netherlands). The R-stent has 316L stainless steel struts with dimensions of 0.09mm x 0.10mm, which are smooth and electropolished, and achieve 17% vessel wall coverage when implanted in the artery. The stent has an open, double helical design with recoil of less than 4% after implantation. The ApoA-I antibody coating was similar to the 100% density ApoA-I coated disks. An untreated R-stent was used as BMS comparator.

**In vivo study**

**Rabbit model.**  The study protocol was reviewed and approved by the Institutional Animal Care and Research Committee at the Academic Medical Center, Amsterdam, The Netherlands (protocol number DCA101095) and conforms to the Directive 2010/63/EU of the European Parliament. We used 15 female New Zealand White rabbits (3.0–3.5kg), which were treated with acetylsalicylic acid 38mg/day started 5 days prior to stent implantation. The rabbit model of balloon-induced artery injury is an established model to test intravascular stent devices since it is characterized by fast development of intima hyperplasia (described in detail in S2 Text).[21–23] In short, after induction of anaesthesia, stents were placed via cannulation of the left
carotid artery, followed by endothelial denudation by pulling an inflated balloon through the iliac arteries. Directly thereafter, ApoA-I coated versus BMS stents were pair wise implanted in both endothelial denudated iliac arteries. During the experiment, rabbits had free access to food (AB-diets, high fibre complete diet).

At 28 days after stenting, the rabbits were anesthetized. Via the abdominal cavity, the retroperitoneal infrarenal aorta was cannulated with an 18G cannula and after intravenous injection of heparin 200IU/kg, angiography of the iliac arteries was performed. Subsequently, the animals were euthanized and the iliac arteries were flushed with saline, followed by perfusion-fixation using Neutral Buffered Formalin (NBF). The stented arteries were taken over a distance from the aorta-iliac bifurcation to one cm distal of the stent, fixated in NBF for 24 hours and subjected to the tissue embedding procedure.

After dehydration, the harvested arteries were stepwise embedded in MMA/BMA mix in a 1:1 ratio and allowed to harden for 24 hours under a vacuum at 4°C. Using a microtome with diamond knife, 10 μm thick transversal sections were cut from 3 regions (proximal, middle and distal) of the stented arteries and 2 peri-stent regions proximal and distal to the stented artery. The middle region (region 3) is defined as 30 sections taken from the exact centre of the stent. The proximal and distal regions (regions 2 and 4) are defined as the 30 sections cut at a distance from 100μm from the stent edge, inside the stent, inwards. The 2 peri-stent regions (regions 1 and 5) are defined as the 30 sections cut at a distance from 100μm from the stent edge, outside the stent, outwards. Sections were stretched on a 60°C bath of 40% acetone and adhered to glass slides using 70% Ethanol overnight at 60°C under mechanical pressure.

Three randomly selected sections of any of the 5 regions were used for staining of the arterial laminae. Sections were stained using Haematoxilin-eosin staining, Lawson staining and immunohistochemical stainings detecting α-smooth muscle actin (α-SMA), Ki-67, rabbit macrophage-specific monoclonal antibody, von Willebrand factor and fibrin. Details about these stainings and morphometrical analysis are described in detail in S3 and S4 Texts, respectively.

Immunohistochemical analysis was performed by 2 separate reviewers, who were both blinded for type of stent coating. The mean score per stent was based on the average score of 2 randomly selected slides taken from both the proximal and distal stented area. Cell proliferation, inflammation, fibrin deposition and endothelialisation of the stented artery were scored (described in detail in S5 Text).[24–27] One rabbit was sacrificed after 28 days to perform scanning electron microscopy (SEM) on the implanted stents. For this purpose, the stented segment of the iliac artery was fixed in 2% glutaraldehyde and processed for SEM imaging, described in detail in S6 Text).

**Statistical analysis**

Statistics were performed using IBM SPSS statistic (version 19) and graphs were constructed using Prism Graphpad (version 5). Based on previous studies utilizing this bilateral vascular injury in rabbits for a side-to-side comparison of two different stent modalities, we determined that for a difference of 25% in lumen stenosis with a standard deviation of 30% within one animal the minimum number of rabbits needed was 12 (power of 0,80 and a type I error probability of <0,05). Data are expressed as mean ± SD. Significance of differences in *in vitro* tests was tested using one-way ANOVA. Comparisons of histological findings between BMS-stent and ApoA-I-coated stent were made by the Wilcoxon signed ranks test. Comparisons of immunohistochemistry results were made by Wilcoxon signed ranks test. A probability value of \( P < 0.05 \) was considered significant.
Results

In vitro studies

**HMEC-1 cell growth and adhesion.** After 4 days of incubation, the number of HMEC-1 cells on the anti-ApoA-I antibody coated surfaces was significantly higher compared to the isotype-antibody control, independent from antibody concentration (10% and 100%) (Fig 1A; \( \text{p} < 0.05 \)). There was an increased proliferation of HMEC-1 cells after 4 days on the surfaces with the highest density of anti-ApoA-I antibody, compared to those with lower densities (\( \text{p} < 0.05 \)).

The anti-ApoA-I antibody coated surface with the highest antibody density was associated with a higher HMEC-1 adhesion under dynamic conditions as compared to the isotype controls (\( \text{p} < 0.05 \); Fig 1B). No effect on HMEC-1 adhesion was observed for the surfaces with the lowest anti-ApoA-I and anti-ApoB antibody density.

**Thrombin generation.** Fig 2 shows that the anti-ApoA-I antibody coated surfaces that were incubated with HMEC-1 caused a significant prolongation in the thrombin generation time when compared to uncoated surfaces (\( \text{p} < 0.01 \)). In addition, lowered peak thrombin and the total amount of thrombin produced (\( \text{p} < 0.05 \)) was observed as compared to the isotype control. These anticoagulant effects increased with a higher density of the anti-ApoA-I antibody. In contrast, anti-ApoB antibody covered discs had no impact on the thrombin generation.

**Platelet adhesion and activation.** Platelet adhesion to the coated discs was clearly reduced on anti-ApoA-I antibody coated surfaces, particularly at a high density, as compared to the ApoB and isotype control (\( \text{p} < 0.05 \); Fig 3A). Similarly, the ApoB antibody coated surface at high density showed reduced platelet adhesion compared to the isotype control (\( \text{p} < 0.05 \)). To further elucidate the implications of this latter finding we studied the influence of the oxidation state of these lipoproteins, in particular oxidized LDL, on the morphology and activation of the adhered platelets using scanning electron microscopy (Fig 3B). Only in the presence of oxidized LDL we noted significantly increased adhered platelet activation.

In vivo study

All rabbits (\( n = 15 \); weight 3.3kg ± 0.2 kg) were successfully stented, no peri-procedural complications occurred. Two rabbits were euthanized prematurely because of gastrointestinal discomfort and significant (>10%) weight loss at day 11 and day 19 after stenting. At 28 days, the stented iliac arteries of all remaining rabbits were patent.

**Morphometric analysis and scanning electron microscopy analysis.** The Lawson-stained sections were assessed for mean lumen stenosis, intima surface and IM-ratio. As shown in panel A1 of Fig 4, anti-ApoA-I coated stents with a mean lumen stenosis of 23.3% showed stenosis rates similar to the BMS stent (\( \text{P} = 0.77 \)). Comparison of the corresponding regions between the two stent types indicated no significant difference (panel A2). This degree of in-stent stenosis is comparable to the magnitude of stenosis observed by other groups using a similar rabbit model [28–30]. In addition, mean intima surfaces in ApoA-I coated and bare metal stents were 0.81 and 0.84 mm² respectively (\( \text{P} = 0.85 \); panel B1). Consistent with these findings, mean IM-ratios in both stents (3.0 vs. 2.7 for ApoA-I vs. BMS, \( \text{P} = 0.28 \)) were not different (panel C1). With respect to intima surface and IM-ratio, corresponding regions were comparable between the two stent types (panel B2 and C2).

We did observe a trend towards decreased RAM-11 positive regions in the vicinity of struts with the anti-ApoA-I coated stent (Fig 5; \( \text{p} = 0.056 \)). The number of KI-67-positive (proliferating) cells did not differ between the two stents (\( \text{P} = 0.673 \)). No difference was observed in fibrin deposition between the two stent types (\( \text{P} = 0.187 \)). Next to the Von Willebrand staining
reflecting endothelialization, the en face analysis of endothelium using SEM (Fig 6) shows that in both stent types, endothelialization pattern is comparable. Immunohistochemical analysis of
Von Willebrand stained slides showed a trend to an increased grade of endothelialization in the ApoA-I coated stents compared to BMS ($P = 0.072$).

**Discussion**

The present study shows that an anti-ApoA-I antibody coated surface, saturated with HDL, improves endothelial cell adhesion and proliferation with a concomitant decrease in thrombin generation and platelet adhesion *in vitro*. These beneficial features *in vitro* did, however, not translate into improved stent performance *in vivo* in a rabbit model of iliac artery balloon injury. The discrepancy between the *in vitro* and *in vivo* effect of anti-ApoA-I antibody coating may reflect insufficient availability of ApoA1 near the stent struts or limited capacity of HDL to attenuate the vascular injury response in an injury model of intimal hyperplasia.

**In vitro experiments**

The improved endothelial cell adhesion and proliferation in our *in vitro* experiments using anti-ApoA-I coated metal discs endorse the results from earlier experimental studies on the protective functions of HDL. HDL has been shown to exert a protective effect on the endothelium by preventing apoptosis and promoting migration of endothelial cells in *in vitro* models. [31–34] In humans, HDL has consistently been shown to exert a beneficial effect on abnormal
vascular reactivity.[35,36] The concomitant antithrombotic effects of ApoA-I in our in vitro experiments correspond to previous studies reporting antithrombotic effects of HDL. Thus, Fleisher et al showed that human HDL stimulates endothelial cell prostacyclin synthesis in vitro, [37] whereas ApoA-I-Milano resulted in decreased thrombus formation in a rat model.[10] In humans, low HDL has also been recognized as a risk factor for venous thrombotic embolism. [38,39] Mechanistically, HDL has been shown to serve as a carrier of a wide array of proteins affecting the innate immune system and proteolytic cascades.[40] In line, systemic infusion of HDL has been shown to reduce vessel wall inflammation.[41,41,42] Collectively, our in vitro
results lend further support to the concept that the presence of ApoA-I on the stent struts may contribute to a better stent performance \textit{in vivo}.

**Rabbit experiments**

Anti ApoA-I-coated stents were not capable of decreasing the vascular response in a rabbit model of iliac balloon artery injury. Similar degree of stenosis, cell proliferation and
endothelialisation were observed between ApoA-I antibody coated stents and the BMS. The apparent discrepancy between the beneficial effects \textit{in vitro} and the absence of a beneficial effect \textit{in vivo} may have several explanations.

First, since the stent is fenestrated, the majority of the arterial wall area is not covered by the stent struts. In contrast to coatings such as sirolimus and paclitaxel that are delivered into the local environment, the ApoA-I/HDL complex is tightly bound at the surface of the stent strut. The spatial distance between the HDL particles in relation to the lesion area between the struts may have undermined a potentially beneficial effect. In support, there was a trend towards a decreased number of inflammatory cells in the anti ApoA-I-coated stents, as well as a trend to a higher degree of endothelialisation.

Second, increased oxidative modification of fixed HDL combined with overgrowth of stent struts by intimal hyperplasia may reduce the bio-availability and potentially beneficial effects of HDL.\[43\] The latter may even imply that the struts become devoid of HDL delivered from the blood. Attempts to visualize the presence of HDL on stent struts using immunohistochemistry, however, failed due to the plastic embedding of the tissue.\[44\]

\textbf{Study limitations}

Despite that inflammatory, proliferative and thrombotic stimuli within the first two weeks after stent implantation are immense, \[43\] the stent harvest after 28 days may have been too early to detect clinically significant differences between the two stents if in-stent restenosis occurs after longer periods of observation. Therefore, longer observation periods may yet reveal superior performance of the ApoA-I coated stent. Another drawback of the study involves the lack of information regarding the antibody binding-place availability and its effects on circulating HDL recruitment within the stented arterial wall. (S1 Fig)

\textbf{Clinical implications}

Relevance of HDL mediated protection beyond reverse cholesterol transport has been widely acknowledged, whereas its impact on cardiovascular outcome remains to be proven. Positive functional effects are confirmed by our \textit{in vitro} studies with anti ApoA-I antibody coated...
metallic surfaces. The attempt to translate these results to a (pre-) clinical setting has, however, failed. Whereas strategies aimed at increasing local ApoA-I concentration may still prove to be beneficial for long-term stent patency, we were unable to provide *in vivo* support for the use of anti-ApoA-I antibody coated stents to reduce intimal hyperplasia.

Fig 6. Scanning electron microscopy overview. SEM images of a 28-day BMS (upper half) and anti-ApoA-I coated stent (lower half) implanted in the rabbit common iliac artery. High magnification details of stent strut coverage are shown of three randomly chosen spots, next to the low magnification overview in the centre. Complete endothelial lining of the lumen is shown in all high-magnification details, with similar endothelial cell aspect.

doi:10.1371/journal.pone.0122836.g006
Supporting Information

S1 Fig. Overview of hypothesis. Schematic overview of the predefined stent regions (lower left) and a transversal section of a stented artery (upper left) The details (A-C) of an anti ApoA-I antibody coated strut compared with the strut of a bare metal stent (BMS; D-F) provide an overview of the hypothesis: anti ApoA-I antibody coated stents are implanted in the pre-injured artery (A). The coated struts attract HDL cholesterol by binding ApoA-I (B). The presence of ApoA-I and HDL prevent restenosis and promotes restoration of the endothelial layer (C). Restenosis occurs in bare metal stents (BMS), which after implantation in the artery (D) does specifically attract ApoA-I and HDL (E) and becomes overgrown by proliferating vascular smooth muscle cells, effectuating stenosis.

S1 Text. Thrombin generation test.

S2 Text. Rabbit stent implantation model.

S3 Text. Histological and immunohistochemical staining.

S4 Text. Morphometric analysis.

S5 Text. Immunohistochemistry and the scoring systems.

S6 Text. Scanning electron microscopy.

Acknowledgments

We thank G. Nakazawa (CVPath Institute, Gaithersburg, USA) for his excellent technical advice concerning the animal model, Y. Marcel (Ottawa Heart Institute Research Corporation, Ottawa, Canada) for manufacturing and supplying the ApoA-I antibody, M.G. Meesterman (Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands), J. van Marle (Department of Cell Biology and Histology, Academic Medical Center, Amsterdam, The Netherlands) for technical support, C.N.W. Belterman and M. Baart for his help with laboratory procedures and Prof. A.H. Zwinderman (Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands) for statistical advise.

Author Contributions

Conceived and designed the experiments: RJB ESGS JIR. Performed the experiments: ACS MLWK LHK RJW. Analyzed the data: ACS MLWK LHK ESGS. Contributed reagents/materials/analysis tools: MLWK LHK ACW CJMV RJW PPT. Wrote the paper: ACS MLWK LHK RJW ACW CJMV RJB ESGS JIR PPT.

References

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011; 123: e18–e209. doi: 10.1161/CIR.0b013e3182009701 PMID: 21166056
2. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991; 324: 13–17. PMID: 1984159

3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370: 937–948. PMID: 17869634

4. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008; 337: a1331. doi: 10.1136/bmj.a1331 PMID: 18757996

5. Bursill CA, Castro ML, Beattie DT, Nakhla S, van d V, Heather AK, et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2010; 30: 1773–1778. doi: 10.1161/ATVBAHA.110.211342 PMID: 20702809

6. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem. 2009; 284: 32336–32343. doi: 10.1074/jbc.M109.047472 PMID: 19783654

7. Wang SH, Yuan SG, Peng DQ, Zhao SP. High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising anti-atherogenic strategy. Clin Exp Immunol. 2010; 160: 137–142. doi: 10.1111/j.1365-2249.2009.04068.x PMID: 20059478

8. Leblond L, Marcel YL. The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A. 2004; 101: 11779–11784. PMID: 15280540

9. Zhang Q, Liu L, Zheng XY. Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells. Int J Cardiol. 2009; 133: 286–292. doi: 10.1016/j.ijcard.2008.11.034 PMID: 19068270

10. Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol. 1999; 19: 378–383. PMID: 9974422

11. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999; 103: 219–227. PMID: 9916134

12. Leblond L, Marcel YL. The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells. J Biol Chem. 1991; 266: 6058–6067. PMID: 1706710

13. Vallyaveettil M, Kar N, Ashraf MZ, Byzova TV, Febbraio M, Podrez EA. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor Bl. Blood. 2008; 111: 1962–1971. PMID: 17993610

14. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992; 99: 683–690. PMID: 1361507

15. Knetsch ML, Aldenhoff YB, Schraven M, Koole LH. Human endothelial cell attachment and proliferation on a novel vascular graft prototype. J Biomed Mater Res A. 2004; 71: 615–624. PMID: 15050782

16. Hemker HC, Giesen PL, Ramjee M, Wagemoor R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost. 2000; 83: 589–591. PMID: 10780322

17. Stevens KN, Knetsch ML, Sen A, Sambhy V, Koole LH. Disruption and activation of blood platelets in contact with an antimicrobial composite coating consisting of a pyridinium polymer and AgBr nanoparticles. ACS Appl Mater Interfaces. 2009; 1: 2049–2054. doi: 10.1021/am900390h PMID: 20355831

18. Chen R, Chen X, Salomon RG, McIntyre TM. Platelet activation by low concentrations of intact oxidized LDL particles involves the PAF receptor. Arterioscler Thromb Vasc Biol. 2009; 29: 363–371. doi: 10.1161/ATVBAHA.108.178731 PMID: 19112165

19. Braet F, De ZR, Wisse E. Drying cells for SEM, AFM and TEM by hexamethyldisilazane: a study on hepatic endothelial cells. J Microsc. 1997; 186: 84–87. PMID: 9159923

20. Ko TM, Lin JC, Cooper SL. Surface characterization and platelet adhesion studies of plasma-sulphopolyethylene. Biomaterials. 1993; 14: 657–664. PMID: 8399962

21. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002; 106: 1867–1873. PMID: 12358643

22. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001; 104: 473–479. PMID: 11468212

23. Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol. 2007; 50: 176–185. PMID: 17616304
24. Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, Swaminathan RV, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 2003; 108: 2788–2804. PMID: 14610008

25. Komowski R, Honig MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31: 224–230. PMID: 9426044

26. Nakazawa G, Yazdani SK, Finn AV, Vorpahl M, Kolodgie FD, Virmani R. Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. J Am Coll Cardiol. 2010; 55: 1679–1687. doi: 10.1016/j.jacc.2010.01.021 PMID: 20394871

27. Wilson GJ, Nakazawa G, Schwartz RS, Huijbregts B, Poff B, Herbst TJ, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009; 120: 141–2. doi: 10.1161/CIRCULATIONAHA.107.730010 PMID: 19564562

28. Wang HS, Nam HY, Kim JM, Hahm DH, Nam SH, Kim KL, et al. Effects of curcumin for preventing restenosis in a hypercholesterolemic rabbit iliac artery stent model. Catheter Cardiovasc Interv. 2009; 74: 881–888. doi: 10.1002/ccd.22047 PMID: 19466118

29. John MC, Wessely R, Kastrati A, Schomig A, Moner J, Uchihashi M, et al. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC Cardiovasc Interv. 2008; 1: 535–544. doi: 10.1016/j.jcin.2008.08.004 PMID: 19463356

30. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. 2011; 4: 38–46. doi: 10.1161/CIRCINTERVENTIONS.110.957654 PMID: 21205943

31. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von EA, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001; 276: 34480–34485. PMID: 11432865

32. Tauber JP, Cheng J, Gospodarowicz D. Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J Clin Invest. 1980; 66: 696–708. PMID: 7419717

33. Murugesan G, Sa G, Fox PL. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ Res. 1994; 74: 1149–1156. PMID: 8172821

34. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006; 98: 63–72. PMID: 16339487

35. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasomotor dysfunction in early atherosclerosis. Circulation. 1994; 89: 2525–2532. PMID: 8205660

36. Spieker LE, Sudano I, Hurliman D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipidprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002; 105: 1399–1402. PMID: 11914243

37. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 1982; 257: 6653–6655. PMID: 7045092

38. Braekkan SK, Borch KH, Mathiesen EB, Njolstad I, Hansen JB. HDL-cholesterol and future risk of venous thromboembolism: the Tromso Study. J Thromb Haemost. 2009; 7: 1428–1430. doi: 10.1111/j.1538-7836.2009.03481.x PMID: 19453941

39. Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood. 2008; 112: 3448–3451. doi: 10.1182/blood-2008-05-157412 PMID: 18614761

40. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007; 117: 746–756. PMID: 17332893

41. Patel S, Di Bartolo BA, Nakhiha S, Heather AK, Mitchell TW, Jessup W, et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis. 2010; 212: 392–397. doi: 10.1016/j.atherosclerosis.2010.05.035 PMID: 20609437

42. Spieker LE, Ruschitzka F, Luscher TF, Noll G. HDL and inflammation in atherosclerosis. Curr Drug Targets Immune Endocr Metabol Disord. 2004; 4: 51–57. PMID: 15032626

43. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol. 1998; 81: 4E–6E. PMID: 9551587

44. Wolf E, Roser K, Hahn M, Welkerling H, Delling G. Enzyme and immunohistochemistry on undecalciﬁed bone and bone marrow biopsies after embedding in plastic: a new embedding method for routine application. Virchows Arch A Pathol Anat Histopathol. 1992; 420: 17–24. PMID: 1539447